Correction: miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer
Saved in:
Main Authors: | Claire Corcoran, Sweta Rani, Susan Breslin, Martina Gogarty, Irene M Ghobrial, John Crown, Lorraine O’Driscoll |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2025-01-01
|
Series: | Molecular Cancer |
Online Access: | https://doi.org/10.1186/s12943-025-02251-8 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Exosomal miR-543 Inhibits the Proliferation of Ovarian Cancer by Targeting IGF2
by: Shupei Zhang, et al.
Published: (2022-01-01) -
Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer
by: Satomi Watanabe, et al.
Published: (2019-03-01) -
Role of Fcγ receptors in HER2-targeted breast cancer therapy
by: Hope S Rugo, et al.
Published: (2022-01-01) -
Comparison of HER2-Targeted Antibodies for Fluorescence-Guided Surgery in Breast Cancer
by: Solmaz AghaAmiri, et al.
Published: (2021-01-01) -
Molecular characterization and potential therapeutic roles of miR125a in HER-2 positive gastric cancer
by: Afraa Mamoori, et al.
Published: (2023-07-01)